US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Menlo Therapeutics Inc.

1.35

0.0000

Volume:- -

Turnover:- -

Market Cap:226.29M

PE:-0.67

High:1.35

Open:1.35

Low:1.35

Close:1.35

52wk High:7.48

52wk Low:1.00

Shares:167.62M

Float Shares:165.81M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.0079

EPS(LYR):-1.6613

ROE:-407.33%

ROA:-68.11%

PB:3.16

PE(LYR):-0.81

Loading ...

Overview Company News Filings

Company Profile

Company Name:

Menlo Therapeutics Inc.

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.menlotherapeutics.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MNLO/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MNLO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MNLO\",,,,,undefined,":{"symbol":"MNLO","market":"US","secType":"STK","nameCN":"Menlo Therapeutics Inc.","latestPrice":1.35,"timestamp":1599249600000,"preClose":1.35,"halted":8,"volume":0,"delay":0,"floatShares":165808346,"shares":167622305,"eps":-2.007892,"marketStatus":"Market Closed","change":0,"latestTime":"09-04 16:00:00 EDT","open":1.35,"high":1.35,"low":1.35,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.007892,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1754899200000},"marketStatusCode":7,"symbolChange":{"newSymbol":"VYNE","executeDate":"2020-09-08"},"adr":0,"adrRate":0,"listingDate":1516856400000,"exchange":"NASDAQ","adjPreClose":1.35,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MNLO\",,,,,undefined,":{"symbol":"MNLO","floatShares":165808346,"roa":"-68.11%","roe":"-407.33%","lyrEps":-1.661279,"shares":167622305,"dividePrice":0,"high":1.35,"amplitude":0,"preClose":1.35,"low":1.35,"week52Low":1,"pbRate":"3.16","week52High":7.48,"institutionHeld":0,"latestPrice":1.35,"eps":-2.007892,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.007892,"open":1.35},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MNLO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2020-09-08","symbol":"MNLO","oldSymbol":"MNLO","defaultRemindTime":1599571800000,"newSymbol":"VYNE","exchange":"NASDAQ","type":"symbolChange","dateTimestamp":1599537600000},{"market":"US","date":"2020-08-06","symbol":"MNLO","fiscalQuarterEnding":"2020/06","expectedEps":-0.21,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1596686400000,"reportTimeType":"post","actualEps":-1.21},{"market":"US","date":"2020-05-11","symbol":"MNLO","fiscalQuarterEnding":"2020/03","expectedEps":-0.5,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1589169600000,"reportTimeType":"pre","actualEps":-0.95},{"market":"US","date":"2020-03-03","symbol":"MNLO","fiscalQuarterEnding":"2019/12","expectedEps":-0.83,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1583211600000,"reportTimeType":"post","actualEps":-0.89},{"market":"US","date":"2019-11-06","symbol":"MNLO","fiscalQuarterEnding":"2019/09","expectedEps":-0.76,"name":null,"time":"","type":"earning","dateTimestamp":1573016400000,"reportTimeType":"","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MNLO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MNLO\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MNLO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MNLO","date":"2020-09-04","current":-0.861379,"percent":0.969799,"low":-4.152726,"twenty":-3.113588,"median":-2.64737,"eighty":-1.642182,"high":-0.661214,"avg":-2.452631,"sd":0.855241,"marketCap":231413048},"quantilePoints":[{"date":"2020-08-14","current":-1.011185,"twenty":-3.142293,"median":-2.687596,"eighty":-1.708884,"marketCap":271658796},{"date":"2020-08-21","current":-0.979975,"twenty":-3.138466,"median":-2.679178,"eighty":-1.670394,"marketCap":263274265},{"date":"2020-08-28","current":-0.892589,"twenty":-3.126984,"median":-2.668858,"eighty":-1.654427,"marketCap":239797579},{"date":"2020-09-04","current":-0.861379,"twenty":-3.113588,"median":-2.64737,"eighty":-1.642182,"marketCap":231413048}],"updateTime":1754720783764},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.menlotherapeutics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.021},{"period":"3month","weight":0.1291},{"period":"6month","weight":0.0606},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.0872}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.","exchange":"NASDAQ","name":"Menlo Therapeutics Inc.","nameEN":"Menlo Therapeutics Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"MNLO\",market:\"US\",,,undefined,":null}}